New injection shows promise for severe eczema relief in major trial
NCT ID NCT06468956
Summary
This large Phase 3 study is testing whether an injectable medication called SHR-1819 can safely reduce symptoms in adults with moderate to severe atopic dermatitis (eczema). Researchers are comparing the drug against a placebo in 652 participants to see if it significantly improves skin redness, thickness, and itching over 16 weeks. The goal is to provide better long-term control for people whose eczema isn't well managed by standard creams.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Fudan University HuaShan Hospital
Shanghai, Shanghai Municipality, 200040, China
Conditions
Explore the condition pages connected to this study.